Advertisement

Topics

SU2C researchers find promising treatment strategy for stage 1-3 NSCL cancer patients

20:00 EDT 15 Apr 2018 | AAAS

(Entertainment Industry Foundation) A new, innovative approach to lung cancer treatment, administration of immunotherapy prior to surgery yielded encouraging outcomes in findings from SU2C-CRI Dream Team researchers. Two doses of anti-PD1 immunotherapy nivolumab several weeks prior to surgery was found to be safe; 45 percent of the trial patients showed little evidence of disease upon follow-up; and patients' immune systems intercepted circulating tumor cells to potentially prevent recurrence and metastasis, consistent with SU2C's research focus on Cancer Interception.

Original Article: SU2C researchers find promising treatment strategy for stage 1-3 NSCL cancer patients

NEXT ARTICLE

More From BioPortfolio on "SU2C researchers find promising treatment strategy for stage 1-3 NSCL cancer patients"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Lung Cancer
Lung cancer is the uncontrolled cell growth in tissues of the lung. Originating in the lungs, this growth may invade adjacent tissues and infiltrate beyond the lungs. Lung cancer, the most common cause of cancer-related death in men and women, is respons...